

## 1 High Seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers

2  
3 Tesfaye Gelanew<sup>1\*</sup>, Berhanu Seyoum<sup>1</sup>, Andargachew Mulu<sup>1</sup>, Adane Mihret<sup>1</sup>, Markos Abebe<sup>1</sup>, Liya  
4 Wassie<sup>1</sup>, Baye Gelaw<sup>2</sup>, Abebe Sorsa<sup>3</sup>, Yared Merid<sup>4</sup>, Yilkal Muchie<sup>5</sup>, Zelalem Teklemariam<sup>6</sup>, Bezalem  
5 Tesfaye<sup>1</sup>, Mahlet Osman<sup>1</sup>, Gutema Jebessa<sup>1</sup>, Abay Atinafu<sup>1</sup>, Tsegaye Hailu<sup>1</sup>, Antenehe.Habte<sup>1</sup>, Dagaga  
6 Kenea<sup>3</sup>, Anteneh Gadissa<sup>4</sup>, Desalegn Admasu<sup>6</sup>, Emmet Tesfaye<sup>4</sup>, Timothy A. Bates<sup>7</sup>, Jote Bulcha<sup>8</sup>, Rea  
7 Tschopp<sup>1,9</sup>, Dareskedar Tsehay<sup>1</sup>, Kim Mullholand<sup>10</sup>, Rawleigh Howe<sup>1</sup>, Abebe Genetu<sup>1</sup>, Fikadu G.  
8 Tafesse<sup>7\*#</sup> and Alemseged Abdissa<sup>1\*#</sup>

9  
10  
11 <sup>1</sup>Armauer Hansen Research Institute, Addis Ababa Ethiopia

12 <sup>2</sup>Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of  
13 Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

14 <sup>3</sup>Arsi University, Asella College of Health Sciences, Asella, Ethiopia

15 <sup>4</sup>Hawassa University, College of Medicine and Health Sciences, Department of Medical Microbiology,  
16 Hawassa, Ethiopia

17 <sup>5</sup>All Africa Leprosy and Tuberculosis Rehabilitation and Training Center (ALERT Center) Hospital,  
18 Addis Ababa, Ethiopia

19 <sup>6</sup>College of Health and Medical Sciences, Department of Medical Laboratory Sciences, Haramaya  
20 University, Harar, Ethiopia

21 <sup>7</sup>Department of Molecular Microbiology & Immunology, Oregon Health & Sciences University, OR,  
22 USA

23 <sup>8</sup>Horae Gene Therapy Center, University of Massachusetts Medical School, MA, USA

24 <sup>9</sup>Swiss tropical and Public Health Institute, Basel, Switzerland

25 <sup>10</sup>London School of Hygiene and Tropical Medicine, London, UK

26  
27 # Authors contributed equally.

28  
29 \*Correspondence to: Tesfaye Gelanew ([tesfaye.gelanew@ahri.gov.et](mailto:tesfaye.gelanew@ahri.gov.et)); Alemseged Abdissa  
30 ([alemseged.abdissa@ahri.gov.et](mailto:alemseged.abdissa@ahri.gov.et)) and Fikadu G. Tafesse ([tafesse@ohsu.edu](mailto:tafesse@ohsu.edu))

52 **Abstract**

53 **Background**

54 COVID-19 pandemic has a devastating impact on the economies and health care system of sub-Saharan  
55 Africa. Healthcare workers (HWs), the main actors of the health system, are at higher-risk because of  
56 their occupation. Serology-based estimates of SARS-CoV-2 infection among HWs represent a measure of  
57 HWs' exposure to the virus and a guide to the prevalence of SARS-CoV-2 in the community. This  
58 information is currently lacking in Ethiopia and other African countries. This study aimed to develop an  
59 in-house antibody testing assay, assess the prevalence of SARS-CoV-2 antibodies among Ethiopian high-  
60 risk frontline HWs.

61  
62 **Methods and findings:** A cross-sectional seroprevalence study was conducted among HWs in five public  
63 hospitals located in different geographic regions of Ethiopia. Socio-demographic and clinical data were  
64 collected using questionnaire-based interviews. From consenting HWs, blood samples were collected  
65 between December 2020 and February 2021, the period between the two peaks of COVID-19 in Ethiopia.  
66 The collected sera were tested using an in-house immunoglobulin G (IgG) enzyme-linked immunosorbent  
67 assay (ELISA) for SARS-CoV-2 specific antibodies on sera collected from HWs. Of 1,997 HWs who  
68 provided a blood sample, demographic and clinical data, 50.5% were female, 74.0% had no symptoms  
69 compatible with COVID-19, and 29.0% had history of contact with suspected or confirmed patient with  
70 SARS-CoV-2 infection. The overall seroprevalence was 39.6%. The lowest (24.5%) and the highest  
71 (48.0%) seroprevalence rates were found in Hiwot Fana Specialized Hospital in Harar and ALERT  
72 Hospital in Addis Ababa, respectively. Of the 821 seropositive HWs, 224(27.3%) had history of  
73 symptoms consistent with COVID-19. A history of close contact with suspected/confirmed COVID-19  
74 cases was strongly associated with seropositivity (Adjusted odds Ratio (AOR) =1.4, 95% CI 1.1-1.8;  
75 p=0.015).

76  
77 **Conclusion:** High SARS-CoV-2 seroprevalence levels were observed in the five Ethiopian hospitals.  
78 These findings highlight the significant burden of asymptomatic infection in Ethiopia, and may reflect the  
79 scale of transmission in the general population.

80  
81 **Key words:** SARS-CoV-2, COVID-19, RBD, ELISA, seroprevalence, antibodies, Ethiopia

82  
83 **Funding** This seroprevalence study was funded by Noard, and Sida core fund, and the Ethiopian Ministry  
84 of Health. Other support was obtained from the Oregon Health & Science University Innovative IDEA  
85 grant 1018784 (to FGT) and National Institutes of Health training grant T32AI747225 (to TAB). The  
86 funders had no role on the study design, execution, interpretation, or where these data were published.

87 **Conflict of Interest**

88 The authors declare no conflict of interest.

89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101

## 102 Author summary

### 103 Why was this study done?

- 104 • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global public health  
105 threat, including Africa
- 106 • The actual morbidity and mortality associated with SARS-CoV-2 infection in Ethiopia  
107 underestimated due to the limited molecular testing capacity.
- 108 • We have limited knowledge about the seroprevalence of COVID-19 among health  
109 workers in Ethiopia.
- 110 • This study aimed to develop an in-house immunoglobulin G (IgG) enzyme-linked  
111 immunosorbent assay (ELISA) for SARS-CoV-2 specific antibodies on sera collected  
112 from HWs and to find out the proportion of healthcare workers who have developed  
113 antibodies specific to SARS-CoV-2 from five public hospitals located in the different  
114 regions of Ethiopia.

### 115 What did the researchers do and find?

- 116 • A cross-sectional seroprevalence study was conducted among HWs in five public  
117 hospitals located in different geographic regions of Ethiopia.
- 118 • Socio-demographic and clinical data were collected from recruited and consented  
119 participants using questionnaire-based interviews.
- 120 • Blood samples were collected from participants between December 2020 and February  
121 2021, the period between the two peaks of COVID-19 in Ethiopia.
- 122 • The collected sera were tested using an in-house ELISA for SARS-CoV-2 specific  
123 antibodies on sera collected from HWs.
- 124 • Approximately 40% of the 1,997 healthcare workers who participated in this study had  
125 antibodies against SARS-CoV-2 infection.
- 126 • No association between seropositivity and study participants' age, gender, occupation,  
127 and comorbid medical conditions.

### 128 What do these findings mean?

- 129 • The observed high seroprevalence among healthcare workers regardless of their  
130 occupation suggests the cryptic but massive SARS-CoV-2 transmission in urban hospital  
131 settings.
- 132 • Most of the seropositive healthcare workers in the present study were asymptomatic, and  
133 might pose a threat to the most vulnerable populations such as individuals with comorbid  
134 medical conditions.
- 135 • Given the low level of vaccine roll-out (1%), this study highlights the need to strengthen  
136 health workers' adherence to personal protection practices such as wearing face masks to

137 protect individuals at high risk of developing severe COVID-19 illness after SARS-CoV-  
138 2 infection.

## 139 140 **1. Introduction**

141 Despite the total population of 1.3 billion, Africa stands out as the region least affected by the Severe  
142 Acute Respiratory Syndrome-Corona-Virus-2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19)  
143 pandemic. As of May 23<sup>rd</sup>, 2021<sup>1</sup>, the total reported case number had risen to 4,748,581 with 128,213  
144 reported deaths, representing 2.9% and 3.7% of global cases and deaths, respectively. The low number of  
145 reported cases and deaths in Africa have been attributed to low testing capacity, younger population,  
146 warmer environments, and the successful implementation of control measures<sup>2</sup>. Also, pre-existing cross-  
147 protective immunity due to the four other less pathogenic human coronaviruses (HCoVs)<sup>3</sup>, Bacillus  
148 Calmette-Guérin (BCG)-vaccination<sup>4</sup>, or recent history of malaria infection may offer some protection  
149 against infection or severe forms of COVID-19<sup>5</sup>.

150 To date, Ethiopia has performed over 2,682,758 real-time reverse transcription-polymerase chain  
151 reactions (RT-PCR) tests for SARS-CoV-2 and reported 268,901 cases and 4,068 deaths since the first  
152 case was detected in the country on March 13, 2020. Almost all testing have been done to confirm SARS-  
153 CoV-2 infection in suspected cases and contacts, as well as both outbound and inbound travelers. Given  
154 the difficulty and cost of RT-PCR-based testing in resource-limited countries like Ethiopia, mildly  
155 affected or asymptomatic individuals are not usually screened, and so the number of confirmed SARS-  
156 CoV-2 infections is likely vastly underestimated<sup>6</sup>. In this context, seroprevalence surveys are of the  
157 utmost importance to assess the proportion of the population that have already developed antibodies  
158 against the virus.

159 Evidence has shown that healthcare workers (HWs) are at higher risk of acquiring the infection than the  
160 general population. This is because their work is likely to require close contact with SARS-CoV-2  
161 infected patients at COVID-19 treatment centers, in emergency rooms and wards, and via virus-  
162 contaminated surfaces. If infected, they can pose a significant risk to vulnerable patients and co-workers<sup>8</sup>.  
163 Thus, assessing the seroprevalence of SARS-CoV-2 antibodies among HWs in Ethiopia will help us  
164 understand COVID-19 spread among health care facilities and to measure the success of public health  
165 interventions. It will also provide an opportunity to compare the disease trajectory in a low-income  
166 setting. A report from London, UK suggested that the rate of asymptomatic SARS-CoV-2 infection  
167 among HWs reflects general community transmission rather than in-hospital exposure<sup>9</sup>. Therefore, a  
168 serosurvey of SARS-CoV-2 was conducted amongst HWs in five public hospitals to estimate the  
169 Seroprevalence of SARS-CoV-2 in urban Ethiopia. We then discuss the implications of our SARS-CoV-2  
170 serosurveillance for frontline healthcare workers and the Ethiopian population at large.

## 171 **2. Methods**

### 172 **Participant recruitment**

173 This cross-sectional study represents a joint effort between the Armauer Hansen Research Institute  
174 (AHRI) and five public hospitals in Ethiopia, namely Gondar, Asella, Hawassa, Hiwot Fana (located in  
175 Harar), and All Africa Leprosy and Tuberculosis Rehabilitation and Training Center (ALERT Center)  
176 hospitals. These participating hospitals were selected because they are among the 11 hospitals located in  
177 different regional states of the country, and are linked to the AHRI's Clinical Research Network. Similar  
178 serosurvey studies for the remaining hospitals linked to the AHRI's CRN are ongoing. Ethical approvals  
179 were obtained from all institutions and written informed consent was obtained from each participant. All  
180 hospital staff (n=7,898) from all five public hospitals were invited to take part in the study through office  
181 memos and notice board announcements. However, only 24.4% of them were volunteered to provide 5  
182 milliliter blood and demographic and clinical data. Demographic and clinical data were obtained using a  
183 structured questionnaire based on WHO SARS-CoV-2 seroprevalence studies (World Health  
184 Organization (WHO, the "Solidarity II" global serologic study for COVID-19)<sup>10</sup>.

### 185 **Sample collection, storage, transportation, and inactivation**

186 Five milliliters of blood were collected in a serum collection tube from each participant using standard  
187 procedures. Sera were separated by centrifugation and stored at  $-20^{\circ}\text{C}$  until transferred to AHRI  
188 laboratory in Addis Ababa, Ethiopia, in a cold box. Inactivation of infectious viruses in serum was  
189 performed by incubation with Triton X-100 to a final concentration of 1% for 1 hour<sup>11</sup> and stored at -  
190  $80^{\circ}\text{C}$  until testing for the presence of SARS-CoV-2 specific antibodies. Serum samples were collected  
191 from December 2020 to February 2021 between the two peaks of SARS-CoV-2 transmissions in Ethiopia  
192 (<https://covid19.who.int/region/afro/country/et>).

### 193 **Enzyme-Linked Immunosorbent Assay (ELISA)**

194 The SARS-CoV-2 spike protein Receptor Binding Domain (RBD)-containing plasmid construct was  
195 cloned as described previously<sup>12</sup>. The RBD protein was then expressed in EXPi293 cells using previous  
196 methods<sup>12</sup>. Then, the purified RBD protein was used as a target antigen to develop our in-house anti-  
197 SARS-CoV-2 RBD IgG detection ELISA. We used  $1\mu\text{g/ml}$  of RBD to coat the microwell plate overnight  
198 at  $4^{\circ}\text{C}$ . The assay is an indirect ELISA, measuring serum IgG against RBD of spike protein SARS-CoV-  
199 2, using a horseradish peroxidase-linked anti-human IgG secondary antibody (Invitrogen, USA).  
200 Supplementary method shows the detail procedure description of our assay (Supplementary Method). We  
201 validated this ELISA using pre-COVID-19 pandemic sera/plasma samples ( $n=365$ ), WHO “Solidarity II”  
202 plasma panels ( $n=5$ ), and sera/plasma samples ( $n=401$ ) collected from a cohort of mild (majority) and  
203 severe COVID-19 patients confirmed by RT-PCR. Detection of RBD-specific IgG antibodies in each  
204 serum sample was done in duplicate microwells of ELISA plate. In each ELISA run, we included  
205 positive and negative controls. Positive and negative control samples were selected by matching their  
206 optical density (OD) readouts with WHO solidarity II plasma panels developed by the United Kingdom’s  
207 National Institute for Biological Standards and Control (NIBSC;20/130, single donor, high-titer  
208 antibody), 20/120 (single donor, relatively high-titer antibody), 20/122 (pool of five donor samples, mid-  
209 titer antibody), 20/124 (low S1, high-nucleocapsid protein antibody titer), 20/126 (low-titer antibody,  
210 20/128, negative control).

### 211 **Optimization and validation of in-house anti-RBD IgG detection ELISA**

212 We noted background signal from the negative controls at a 1:100 dilution of serum. Of 365 pre-COVID-  
213 19 sera, 30 showed optical density (OD) values comparable to the low reactive convalescent WHO  
214 plasma samples. We further optimized the assay by increasing the concentration of skimmed milk powder  
215 and Tween-20 in blocking buffer from 3% to 4% and from 0.05% to 0.1%, respectively, and serum  
216 dilution at 1:200. Except for fourteen pre-COVID-19 samples, the background was significantly reduced  
217 when re-tested false positives, which in turn increased the specificity of our assay without compromising  
218 its sensitivity in WHO positive control samples and serum samples obtained from a cohort of COVID-19  
219 patients.

220 Using our optimized ELISA protocol, we calculated the cut-off value for positivity using pre-COVID-19  
221 pandemic sera collected between 2012 and 2018, and plasma/serum samples collected from cohort of  
222 confirmed COVID-19 patients at different time points of post-onset of symptoms (dps). The definition of  
223 seropositivity represents a greater than 2.5 ratio of sample OD value to the mean OD value of the negative  
224 controls (Fig 1). This definition provides specificity of 97.7% (95% CI, 95.6- 99.0) (Table S1). Our anti-  
225 RBD IgG detection ELISA showed a sensitivity of 67.3% (95% CI 62.3.0-72.3), 75. 8% (95% CI 61.0-  
226 86.0), 100% (95% CI 84.0-100) in serum/plasma samples collected at 1-7 dps, 8-14 dps and  $\geq 15$ dps,  
227 respectively from mostly (>90%) mild and moderate COVID-19 cases confirmed by RT-PCR (Table S2).  
228 This performance is in line with those published for both in-house and commercial assays approved for  
229 emergency use by the FDA<sup>13</sup>.

230 and <https://covid-19-diagnostics.jrc.ec.europa.eu/>].

### 231 **In-house IgG ELISA comparison with commercial anti-SARS-CoV-2 serologic assays**

232 We further compared the relative sensitivity and specificity of our assay with commercially available  
233 SARS-CoV-2 antibody tests: one lateral flow assay (LFA) (Hangzhou Realy Tech Co., LTD) and one  
234 ELISA (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd) following the manufacturers’  
235 instructions using randomly selected small panels (pre-pandemic;  $n=40$ , and COVID-19;  $n=40$ ) from the  
236 large size panels that were used for our assay validation. We found a comparable sensitivity and

237 specificity to those commercially available COVID-19 antibody detection kits depending on the sample  
238 collection date (Table S3 and Table S4). We then utilized this assay to estimate the seroprevalence of  
239 anti-SARS-CoV-2 spike protein RBD IgG antibodies among HWS.

240  
241

### 242 **Data analysis**

243 The data were double entered into REDCap Database Version 8.11. Following data verification and  
244 validation, analysis was done using STATA Version 15.0. Descriptive statistics and the actual number of  
245 cases were used to describe frequency outputs for categorical variables. Figures were generated using  
246 GraphPad Prism Version 9.1. Cross-tabulations were performed to explore and display relationships  
247 between two categorical variables. The overall seroprevalence with 95% CI for anti-SARS-CoV-2 RBD  
248 IgG was calculated by dividing the number of seropositive cases divided by the total number of study  
249 participants from all five hospitals. Apparent SARS-CoV-2 prevalence was stratified by the geographic  
250 location of hospitals, age, sex, self-reported previous history exposure, symptoms, comorbidities, and  
251 further by occupation/department where HWs are working. Bivariate logistic regression was done  
252 between seroprevalence with independent variables such as sex, age, occupation, comorbidity, history of  
253 close contact, and symptoms. Multivariate regression analysis was applied for those variables with a p-  
254 value <0.25 in bivariate analysis to evaluate the strength of association between independent variables  
255 and seropositivity, the outcome variable. A p-value of <0.05 was considered statistically significant.

### 256 **3. Results**

#### 257 **Characteristics of study participants**

258 The total number of HWs in the five participating hospitals was 7,898. Of these, we enrolled 1,997  
259 (24.4%) HWs [from Gondar (n=453); Assela (n=484); ALERT (n=308); Hawassa (n=414); and  
260 Haromaya (n=338)] in the study. Almost half (50.7 %) of the study participants were female. The  
261 majority (85.7%) of the participants belonged to the age groups 25-34 and 35-49 years with the mean age  
262 34 years (range 20-60 years). Of the participants, 559 (28.3%) were nurses, 368 (18.5%) were doctors,  
263 223 (11.3%) were medical laboratory personnel, 345 (17.5%) were administrative staff, and the remaining  
264 24.2% (n=478) did not specify their occupation. In the cohort, 1490 (74.0%) participants were  
265 asymptomatic, 507 (26.0%) had reported one or more symptoms compatible with COVID-19 during the  
266 preceding 4 weeks, and 557 (29.0%) had a history of close contact with suspected or confirmed COVID  
267 cases. Overall, 133 (6.7%) of the participants reported having a history of comorbid medical conditions,  
268 with obesity (1.9%), asthma (1.7%), hypertension (1.5%), and Human Immunodeficiency Virus (HIV)  
269 (1.3%) being the most common. These and other demographic and clinical characteristics of study  
270 participants are summarized in Table 1.

#### 271 **Seroprevalence of SARS-CoV-2 antibodies by geographic locations of participating hospitals, age, sex, healthcare cadre and clinical factors**

273 The overall seroprevalence of SARS-CoV-2 antibodies among HWs from all five studied public hospitals  
274 was 833 of 1,997 (39.6.7% [95% CI 40. 37.4-41.7]). The estimated seroprevalence with 95% CI for each  
275 of the participating hospitals was shown in Fig 2 and Table 1, ranging from 24.5% to 48.0%. We did not  
276 find association between seropositivity and participants' demographic and clinical features given in Table  
277 1, except history of contact with confirmed or confirmed COVID-19 contact. Non-significant  
278 seroprevalence difference was observed between females (42.4% [95% CI 39.4-45.55]) and males (39.6%  
279 [95% CI 36.6-42.7]). However, higher [48.5% [95% CI 44.3-52.6]] seroprevalence found in HWs who  
280 had close contact with COVID-19 case than in HWs who reported no contact (38.1% [95% CI 35.6-  
281 40.7]). Seroprevalence was similar amongst different cadres of the health system, and amongst different  
282 age groups of HWs (Table 1). Slightly higher (44.4% [95% CI 36.1-52.9]) seropositivity against SARS-  
283 CoV-2 was found in comorbid HWs than in HWs who had no comorbidity (40.9% [95% CI 38.7-43.3]).

#### 284 **Factors associated with anti-SARS-CoV-2 RBD IgG antibodies positivity**

285 HWs working at Gondar (AOR=2.8, 95% CI 1.99- 3.87; p=0.001), ALERT (AOR=2.7, 95% CI 1.6-3.1;  
286 p=0.001), Hawassa (Adjusted OR=2.1, 95% CI 1.5-3.2; p=0.001) and Assela (AOR=2.1, 95% CI 1.6-

287 3.1;  $p=0.001$ ) were at higher odds of seropositivity compared to HWs working at Hiwot Fana Specialized  
288 University Hospital (Table 2).

289 Association with seropositivity was further tested for correlation with gender, age, contact, morbidity,  
290 previous COVID symptoms, and occupation using both bivariate and multivariate analyses. However,  
291 only previous history of contact with confirmed or suspected COVID-19 case [COR 1.5 95% (1.3-1.9;  
292  $p=0.0001$ ) and AOR 1.4 (1.1-1.8;  $p=0.015$ )] and having symptoms compatible with COVID-19 in  
293 preceding 4 weeks [COR 1.3 (1.0-1.5)] were found to be associated with seropositivity (Table 2).

#### 294 4. Discussion

295 Interpretation of SARS-CoV-2 serologic test results, except pan Igs Wanti ELISA, has been reported to  
296 be very challenging in Africa due to pre-existing cross-reactive antibodies induced by other pathogens  
297 such as non-SARS-CoV-2 human coronaviruses and malaria parasites<sup>14</sup>. Given the rapid decline of anti-  
298 SARS-CoV-2 nucleocapsid antibodies as compared to the anti-RBD IgG antibody<sup>13</sup>, we developed and  
299 optimized an in-house ELISA that detects anti-SARS-CoV-2 IgG antibodies. Our assay, unlike other  
300 commercially available serologic assays, is affordable and has been validated with a large number of  
301 Ethiopian sera from both pre-COVID-19 and COVID-19 patients from the same regions. Its sensitivity on  
302 convalescent sera from COVID-19 patients confirmed by RT-PCR was found to be as sensitive as the  
303 Wantai pan Ig ELISA (100%), and superior to Realy Tech's IgM/IgG LFA (90%). Also, our in-house  
304 assay displayed 97.7% specificity in randomly selected pre-COVID-19 Ethiopian origin sera, which is  
305 superior to Realy Tech (92.5 %).

306 Seroprevalence studies provide information about the extent of individuals who had exposure to the  
307 virus and help to understand the future course of the pandemic and are key to providing target prevention  
308 and control measures in reducing transmission and severe outcomes<sup>15</sup>. In this study, the overall  
309 seroprevalence of SARS-CoV-2 spike RBD IgG antibodies among HWs was 39.6%, ranging from 24.5%  
310 in the Hiwot Fana Specialized Hospital, Harar to 48.0% in ALERT Hospital located in the capital city,  
311 Addis Ababa. This is not a surprise given Addis Ababa is the epicenter of SARS-CoV-2 transmission in  
312 Ethiopia, and SARS-CoV-2 has been introduced 4 months later in Harar. As a result of which, it is  
313 expected that a higher proportion of HWs in hospitals located in Addis Ababa, including ALERT are  
314 frequently exposed to COVID-19 cases than that HWs working in hospitals located in Harar, where fewer  
315 number cases and deaths had been reported.

316 According to our finding, at least 4 in 10 urban Ethiopian HWs had already been exposed to SARS-CoV-  
317 2 by February 2021 in Ethiopia. This result contrasts with a serosurvey in asymptomatic individuals from  
318 the general population conducted in March 2020 in Addis Ababa (8.8%)<sup>16</sup> and from the household  
319 serosurveys in Jimma (2%) and Addis Ababa (5%) that were conducted during the first wave of the  
320 pandemic-i.e., four months after the first COVID-19 case in Ethiopia<sup>17</sup>. Although this stark  
321 seroprevalence difference between our study and these two previous studies might be explained by  
322 differences in the types of assays employed, lack of personal protective equipment (PPE) and/or  
323 respective cohorts, the most plausible explanation is that the sera for the present serosurveillance study  
324 had been collected after the first wave of the pandemic in Ethiopia, between March 2020 and February  
325 2021.

326 While the high seroprevalence rates observed among the different geographically located hospitals are  
327 approaching those of high-incidence countries like Brazil<sup>18</sup>, they are in agreement with several other  
328 SARS-CoV-2 seroprevalence studies from sub-Saharan Africa that, like Ethiopia, have reported much  
329 lower rates of RT-PCR confirmed cases and deaths. For example, higher anti-SARS-CoV-2 antibody  
330 seroprevalence has been reported in South Sudan (30% to 60.6%)<sup>19</sup>, Democratic Republic of Congo (8%-  
331 36%)<sup>20</sup> and Nigeria (25%-45%)<sup>21</sup> depending on the population sampled and the serological test use. Taken  
332 together these studies indicate that SARS-CoV-2 has spread widely in sub-Saharan Africa<sup>22</sup>. However,  
333 the majority (74.0%) of our study participants never had any symptoms compatible with COVID-19,  
334 suggesting the occurrence of significant burden of asymptomatic infections and its transmissions in the  
335 country, which is now, being reflected in the trend of increasing PCR positivity since January 2021. The  
336 higher proportion of younger HWs (mean age of 34 years), and the fewer participants with comorbidities  
337 (6.7%) may have contributed to the observed high burden of asymptomatic infection among the studied

338 HWs. Malaria, BCG-vaccination, warmer environment, and high prevalence of pre-existing cross-  
339 reactivate against HCoV-229E may have also contributed<sup>3</sup>.  
340 A report from Spain showed a higher (38.3%) seroprevalence of SARS-CoV-2 among HWs<sup>23</sup>. This is  
341 comparable with the present report from Ethiopia, where there were a relatively fewer severe cases and  
342 deaths. Similarly, higher seroprevalence among frontline HWs has been reported in other sub-Saharan  
343 African countries such as in Malawi<sup>24</sup>. These findings and ours highlight the importance of asymptomatic  
344 infections in the African countries. Interestingly, we found no seroprevalence differences between  
345 healthcare occupations including administrative staff. The lack of a dramatic difference between front line  
346 HWs and administrators may be a reflection of the frontline administrative staff are also at high risk and  
347 are poorly protected, or may suggest the level of virus transmission in the general population at large as  
348 previously observed in UK<sup>9</sup>. Nevertheless, further well-designed investigations are required to implement  
349 occupation-specific public health strategies in healthcare facilities.  
350 In the present study, a history of previous close contact with a suspected or confirmed COVID-19 case  
351 was found to be strongly associated with seropositivity; however, this finding contradicts the observed  
352 similar seropositivity between front line HWs and administrators. Similar odds of seropositivity between  
353 males and females were also found although several studies elsewhere reported higher odds of  
354 seropositivity in males<sup>25</sup>. A similar contradictory finding was reported in the Spanish general  
355 population<sup>23</sup>.  
356 Our study has several strengths. These include its use of an in-house developed assay which we optimized  
357 to significantly minimize false positive responses by validating it with both pre-pandemic and pandemic  
358 samples of Ethiopian origin. Most importantly, the study involved a relatively large sample size from five  
359 hospitals located in different geographical locations, providing much needed information about the  
360 COVID-19 pandemic in sub-Saharan Africa.  
361 Despite these strengths, our study has several limitations. First, all hospital staff were invited to take part  
362 in the study, and hence selection bias might have affected our results. Second, recall bias might have  
363 affected the responses to the history of symptoms compatible with COVID-19, and close contact with a  
364 confirmed COVID-19 case, and thereby contributed to the absence of a strong correlation between  
365 seropositivity and these covariates, albeit having close contact with COVID-19 case. Third, our findings  
366 are slightly affected by the accuracy of our assay, with a sensitivity of 100% in convalescent samples  
367 from RT-PCR confirmed COVID-19 cases and specificity of 97.7% in pre-COVID-19 samples.  
368 However, even this slight overestimation of the apparent seroprevalence associated with the assay  
369 specificity is likely to be matched by the proportion of study participants who might be infected and yet  
370 not produce humoral immune responses at the time of blood sample collection.  
371 In conclusion, we developed an in-house IgG ELISA that meets the WHO requirements to be utilized for  
372 SARS-CoV-2 serosurveillance studies. This seroprevalence study revealed a remarkably high  
373 seroprevalence (40-48%) of SARS-CoV-2 among HWs in the five public hospitals; with slight  
374 differences amongst hospitals, except Hiwot Fana Specialized Hospital in which relatively lowest (24.5%)  
375 seroprevalence was found. We found no seroprevalence rate differences between front line HWs and  
376 administrative staff, indicating the observed high seroprevalence of SARS-CoV-2 might also be a  
377 reflection of the community transmission. Taken together these findings suggest extensive cryptic  
378 circulation (asymptomatic transmission) of SARS-CoV-2 in Ethiopia. Whether the detected anti-SARS-  
379 CoV-2 antibodies can persist adequately and confer protection from subsequent infections to those HWs  
380 who had or had not received COVID-19 vaccine will require further immunological investigation.

### 381 **Acknowledgements**

382 We thank study participants and AHRI's SARS-CoV-2 diagnostic and research team members. We also  
383 thank Mr. Mekonnen Ashagarie, Director of American Health and Home Care, MA, USA for the non-  
384 technical support.

### 385 **Contributors**


386 TG, AM, AMi MA, AA and FG conceived the study. TG, BS, AM, and AA wrote the first draft of the  
387 protocol, and revised by all authors. TG, AM, MA, AA and FGT developed the serologic assay, TAB

388 purified the antigen. TG, BS, AM, AMi and AA coordinated the sample collection. BG, AS, YM, YM,  
389 ZT, DK, AG, DA and ET collected the blood samples and data. BT, MO, GJ, AA, AH and DT conducted  
390 the sample testing, TH cleaned the data, TH and TG analysed the data, TG accessed and verified the data  
391 underlying the study and take responsibility for the data. TG and AA drafted the manuscript. All authors  
392 edited the final manuscript. All authors contributed to study design, revising the protocol and the  
393 manuscript for important intellectual content. TG, AA, FGT were responsible for the decision to submit  
394 for publication, and approved the final submitted version of the manuscript.

## 395 **References**

- 396 1 Coronavirus Disease 2019 (COVID-19) – Africa CDC. <https://africacdc.org/covid-19/> (accessed  
397 March 18, 2021).
- 398 2 Gaye B, Khoury S, Cene CW, *et al.* Socio-demographic and epidemiological consideration of Africa’s  
399 COVID-19 response: what is the possible pandemic course? *Nat Med* 2020; **26**: 996–9.
- 400 3 Tso FY, Lidenge SJ, Peña PB, *et al.* High prevalence of pre-existing serological cross-reactivity  
401 against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. *Int J*  
402 *Infect Dis* 2021; **102**: 577–83.
- 403 4 Yitbarek K, Abraham G, Girma T, Tilahun T, Woldie M. The effect of Bacillus Calmette-Guérin  
404 (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: Implications for  
405 the COVID-19 pandemic. *Vaccine* 2020; **38**: 6374–80.
- 406 5 Kalungi A, Kinyanda E, Akena DH, Kaleebu P, Bisangwa IM. Less Severe Cases of COVID-19 in  
407 Sub-Saharan Africa: Could Co-infection or a Recent History of Plasmodium falciparum Infection Be  
408 Protective? *Front Immunol* 2021; **12**: 565625.
- 409 6 Verity R, Okell LC, Dorigatti I, *et al.* Estimates of the severity of coronavirus disease 2019: a model-  
410 based analysis. *Lancet Infect Dis* 2020; **20**: 669–77.
- 411 7 WHO-2019-nCoV-Seroepidemiology-2020.2-eng.pdf.  
412 [https://apps.who.int/iris/bitstream/handle/10665/332188/WHO-2019-nCoV-Seroepidemiology-2020.2-](https://apps.who.int/iris/bitstream/handle/10665/332188/WHO-2019-nCoV-Seroepidemiology-2020.2-eng.pdf?sequence=1&isAllowed=y)  
413 [eng.pdf?sequence=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/332188/WHO-2019-nCoV-Seroepidemiology-2020.2-eng.pdf?sequence=1&isAllowed=y) (accessed March 18, 2021).
- 414 8 Garcia-Basteiro AL, Moncunill G, Tortajada M, *et al.* Seroprevalence of antibodies against SARS-  
415 CoV-2 among health care workers in a large Spanish reference hospital. *Nat Commun* 2020; **11**: 3500.
- 416 9 Treibel TA, Manisty C, Burton M, *et al.* COVID-19: PCR screening of asymptomatic health-care  
417 workers at London hospital. *Lancet Lond Engl* 2020; **395**: 1608–10.
- 418 10 ‘Solidarity 2’ global serologic study for COVID-19. [https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-2-global-serologic-study-for-covid-19)  
419 [coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-2-global-serologic-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-2-global-serologic-study-for-covid-19)  
420 [study-for-covid-19](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-2-global-serologic-study-for-covid-19) (accessed March 18, 2021).
- 421 11 Isho B, Abe KT, Zuo M, *et al.* Persistence of serum and saliva antibody responses to SARS-CoV-2  
422 spike antigens in COVID-19 patients. *Sci Immunol* 2020; **5**. DOI:10.1126/sciimmunol.abe5511.
- 423 12 Bates TA, Weinstein JB, Farley S, Leier HC, Messer WB, Tafesse FG. Cross-reactivity of SARS-CoV  
424 structural protein antibodies against SARS-CoV-2. *Cell Rep* 2021; **34**: 108737.
- 425 13 openFDA. <https://open.fda.gov/apis/device/covid19serology/> (accessed April 15, 2021).


- 426 14 Emmerich P, Murawski C, Ehmen C, *et al.* Limited specificity of commercially available SARS-CoV-  
427 2 IgG ELISAs in serum samples of African origin. *Trop Med Int Health TM IH* 2021; published online  
428 March 5. DOI:10.1111/tmi.13569.
- 429 15 Clapham H, Hay J, Routledge I, *et al.* Seroepidemiologic Study Designs for Determining SARS-COV-  
430 2 Transmission and Immunity. *Emerg Infect Dis* 2020; **26**: 1978–86.
- 431 16 Alemu BN, Addissie A, Mamo G, *et al.* Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis  
432 Ababa, Ethiopia. *bioRxiv* 2020; : 2020.10.13.337287.
- 433 17 Abdella S, Riou S, Tessema M, *et al.* Prevalence of SARS-CoV-2 in urban and rural Ethiopia:  
434 Randomized household serosurveys reveal level of spread during the first wave of the pandemic.  
435 *EClinicalMedicine* 2021; **35**. DOI:10.1016/j.eclinm.2021.100880.
- 436 18 Buss LF, Prete CA, Abraham CM, *et al.* COVID-19 herd immunity in the Brazilian Amazon. *medRxiv*  
437 2020; : 2020.09.16.20194787.
- 438 19 Wiens KE, Mawien PN, Rumunu J, *et al.* Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Juba,  
439 South Sudan: a population-based study. *MedRxiv Prepr Serv Health Sci* 2021; published online March  
440 12. DOI:10.1101/2021.03.08.21253009.
- 441 20 Mukwege D, Byabene AK, Akonkwa EM, *et al.* High SARS-CoV-2 Seroprevalence in Healthcare  
442 Workers in Bukavu, Eastern Democratic Republic of Congo. *Am J Trop Med Hyg* 2021; **104**: 1526–30.
- 443 21 SARS-CoV-2 Seropositivity in Asymptomatic Frontline Health Workers in Ibadan, Nigeria in: The  
444 American Journal of Tropical Medicine and Hygiene Volume 104 Issue 1 (2020).  
445 <https://www.ajtmh.org/view/journals/tpmd/104/1/article-p91.xml> (accessed April 13, 2021).
- 446 22 Usuf E, Roca A. Seroprevalence surveys in sub-Saharan Africa: what do they tell us? *Lancet Glob*  
447 *Health* 2021; **0**. DOI:10.1016/S2214-109X(21)00092-9.
- 448 23 Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based  
449 seroepidemiological study - The Lancet. [https://www.thelancet.com/journals/lancet/article/PIIS0140-](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31483-5/fulltext)  
450 [6736\(20\)31483-5/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31483-5/fulltext) (accessed April 13, 2021).
- 451 24 High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in  
452 urban Malawi | medRxiv. <https://www.medrxiv.org/content/10.1101/2020.07.30.20164970v3>  
453 (accessed April 13, 2021).
- 454 25 Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and  
455 associated factors in healthcare workers: a systematic review and meta-analysis. *J Hosp Infect* 2021;  
456 **108**: 120–34.
- 457



458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476

**Figure 1. Validation of the SARS-CoV-2 RBD specific IgG antibody detection ELISA.** The value on the y-axis represents the ratio of OD<sub>450</sub> nm to the average mean OD<sub>450</sub> nm of the negative controls. The broken black line represents the cut-off value (2.5). We tested a total of 405 serum/plasms samples collected from cohort of mild and moderate (93.6%) and severe Ethiopian COVID-19 patients confirmed by RT-PCR (represented in red color). Of these 325 samples were collected during 0-7 days post-onset of symptoms (dps); 52 were collected during 8-14 dps, and 17 were collected within 15-28 dps (Table S2). We also tested serum/plasma samples collected from 365 Ethiopian individuals before the global COVID-19 pandemic, represented in blue color (Table S1).

477  
478



479  
480  
481  
482  
483  
484  
485  
486  
487  
488

**Figure 2.** A map of Ethiopia showing the location of the five hospitals from which a total of 1997 healthcare workers enrolled between December 2020 and February 2021 (a), and the corresponding seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (b). The y-axis of Fig 2b represents the study hospitals. The x-axis of Fig 2b shows crude seroprevalence rates (%) with 95% confidence intervals estimated by dividing the number of participants tested seropositive for immunoglobulin G (IgG) antibodies elicited against the receptor binding domain (RBD) of the spike protein of SARS-CoV-2 to the total number of participants who provided sera and were tested.

489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502

503

504 **Table 1.** Participant characteristics with interview data (n=1,997) and seroprevalence, Ethiopia, 2021.

Characteristics	N	%	Crude seroprevalence (%), 95% CI
<b>Gender</b>			
Male	980	49.3	39.6 (36.6-42.7)
Female		51.7	42.37(39.4-45.5)
<b>Age (in years)</b>			
19-24	169	8.8	44.0(36.7-51.7)
25-34	918	46.0	41.6(38.4-44.8)
35-49	792	39.7	39.7(36.4-43.0)
≥50	115	5.8	41.7(33.00-51.0)
<b>Morbidity</b>			
Yes	133	6.7	44.4(36.1-52.9)
No	1864	93.3	40.9(38.7-43.3)
<b>COVID-19</b>			
Symptomatic	507	26.0	39.9(37.4-42.4)
Asymptomatic	1490	74.0	45.2(40.9-49.5)
<b>Contact</b>			
Yes	557	29.0	48.5(44.3-52.6)
No	1362	71.0	38.1(35.6-40.7)
<b>Hospitals</b>			
ALRET	308	15.4	48.1(40.3-53.6)
Asella	484	24.2	40.7(36.4-45.1)
Gondar	453	22.6	44.7(40.12-49.3)
Hawassa	414	20.7	44.8(40.05-49.)
Hiwot Fana	338	17.0	24.6(20.3-29.4)
<b>Occupation</b>			
Doctor	368	18.7	40.5(35.6-45.6)
Nurse	559	28.3	41.9(37.7-45.8)
Lab Tech	223	11.3	46.2(39.7-52.8)
Administrator	345	17.4	39.1(34.1-44.4)
Others	478	24.2	43.5(38.7-48.4)

506 N is the total number of participants included in each category.

507 % indicates proportion of participants that fell within each category.

508

509

510

511

512

513

514

515

516

517

518

519 **Table 2.** Odds ratios (OR) of seropositivity by general characteristics of study participants, Ethiopia, 2021.

Variable	Adjusted OR (95% CI)	p-value
<b>Hospital</b>		
Hiwot Fana	1	
ALERT	2.7(1.6-3.1)	<b>0.0001</b>
Assela	2.2 (1.6-3.1)	<b>0.0001</b>
Gondar	2.8(2.0- 3.9)	<b>0.0001</b>
Hawassa	2.2 (1.5-3.2)	<b>0.0001</b>
<b>Sex</b>		
Male	1	
Female	1.1(0.92-1.4)	0.222
<b>Age (in years)</b>		
19-24	1.27(0.9-1.9)	0.226
25-34	1.1(0.9-1.5)	0.254
35-49	1	
>=50	1.2(0.8-1.8)	0.479
<b>Contact</b>		
No	1	
Yes	1.4 (1.1-1.8)	<b>0.015</b>
<b>COVID-19</b>		
Asymptomatic	1	
Symptomatic	1; (0.8-1.2)	0.785
<b>Occupation</b>		
Doctor	1	
Nurse	1.0 (0.8-1.4)	0.809
Lab Technician	1.3 (0.9-1.9)	0.131
Administration	1.01 (0.8-1.5)	0.766
Others	1.3(0.9-1.7)	0.150

539

540

541

542

543

544 **Table S1.** The Specificity of RBD IgG ELISA among pre-COVID-19 pandemic sera (n=365)

Negative Samples	Total number tested	Negative	Specificity (%)	95% CI
Pre-COVID-19 pandemic sera	364	350	97.7	95.6-99.0
NIBS UK adults pooled plasma	1	1		
Total	365	351	97.7	95.6-99.0

545

546 **Table S2.** Sensitivity of RBD IgG ELISA among cohort COVID-19 patients (n=405) confirmed by RT-PCR.

Sample collection	Total N Tested	Positive	Sensitivity (%)	95% CI
1-7dps	336	226	67.3	62.0-72.3
8-14dps	52	39	75.0	61.0-86.0
15-21dps	13	13	100.0	75.29-100.0
NIBSC UK COVID-19 convalescent plasma	4	4	100.0	-
Total Convalescent samples s	17	17	100.0	84.2-100

547

548

549 **Table S3. Percentage of positive specimens (n=40) from patients who tested positive for SARS-CoV-2 by**  
 550 **DAA<sub>n</sub> RT-PCR**

Assay	Sample collection	IgM		IgG		Pan igs	
		%	95% CI	%	95% CI	%	95%
In-house ELISA <sup>a</sup>							
	1-7 dps <sup>b</sup>	na	na	73.3	44.9- 92.2	na	na
	8-14 dps			86.7	59.5- 98.3		
	14-21 dps	na	na	100.0	69.1-100.0	na	na
Wantai ELISA							
	1-7 dps	na	na	na	na	66.7	38.4-88.2
	8-14 dps					86.7	59.5- 98.3
	14-21 dps	na	na	na	na	100.0	69.2-100.0
REALY LFA <sup>c</sup>							
	1-7 dps	80.0	51.9- 95.7	80.0	51.9- 95.7	na	na
	8-14 dps	86.7	59.5- 98.3	80.0	51.9- 95.7		
	15-28 dps	90.0	55.5-99.0.	90.0	55.5-99.8	na	na

551 <sup>a</sup>dps=days post symptoms; <sup>a</sup> ELISA=Enzyme-Linked Immunosorbent Assay; <sup>b</sup> na=not applicable; <sup>bc</sup> LFA=Lateral  
 552 Flow Assay

553 **Table S4. Specificity of RBD IgG ELISA in pre-covid plasma/serum specimens (n=40) collected before**  
 554 **COVID-19 pandemic**

Assay	Specificity (%)	95% CI
In-house ELISA	97.5	86.8- 99.9
Wantai ELISA	100.0	89.72-100.0
Realty LFA	92.5	79.6-98.4

555

556 **Supplementary Method**

557 Microtiter plates were coated with purified recombinant proteins of receptor binding domain of the spike protein of  
 558 SARS-CoV-2 (100 µl/well) diluted in phosphate buffered saline, PBS (pH 7.4) at concentration 1 µg/mL and  
 559 incubated overnight at 4 °C. Next day, excess unbound antigen was removed and thereafter microtiter plates were  
 560 blocked with 300 µl/well of 4% skimmed milk with PBS plus 0.1% Tween-20 (w/v) for 2 hours at room  
 561 temperature (RT). Following blocking step, microtiter plates washed 3X with PBS plus 0.05% Tween-20 (PBST)  
 562 and thereafter 100 µl/ml of serum sample diluted at 1:200 in blocking buffer was added and incubated at RT for 60  
 563 min. Following incubation and 5X washes with PBST, 100 µl/well of horseradish peroxidase-conjugated anti-human  
 564 immunoglobulin G (IgG) (Invitrogen, USA) diluted at 1:5000 in blocking buffer was added and incubated for 1 h  
 565 at RT. After 5X washes, the reaction was visualized by adding 75 µl/well 3,3',5,5'-Tetramethylbenzidine (TMB)  
 566 liquid substrate (BioRad, USA) and incubating at RT in the dark for 10-15 min. The reaction was then stopped with  
 567 75 µl/well TMB stop solution. The optical density (OD) was measured at 450 nm filter on ELISA LT-45000  
 568 microplate reader. Each sample was tested in duplicate.